HomeAI · summaries
Storia in 3 fonti
FDA approves Tryngolza to reduce triglycerides, pancreatitis risk in hypertriglyceridemia
The FDA has approved olezarsen as the first and only therapy, alongside diet, to lower triglycerides and acute pancreatitis risk in patients with severe hypertriglyceridemia, according to a manufacturer press release.Olezarsen (Tryngolza, Ionis Pharmaceuticals), an apolipoprotein C-III inhibitor, is administered once monthly by autoinjector and is available in 50 mg and 80 mg doses. As Healio
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
medpagetoday.com
Severe Hypertriglyceridemia Drug Approved to Reduce Triglycerides, Pancreatitis Risk
Olezarsen indicated as an adjunct to diet
- ·
morningstar.com
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in…
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia…
